Hyaluronidase-Sensitive Nanoparticle Templates for Triggered Release of HIV/AIDS Microbicide In Vitro
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 2
Abstract
The online version of this article (doi:10.1208/s12248-013-9546-7) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Vivek Agrahari, Chi Zhang, Tao Zhang, Wenjing Li, Todor K. Gounev, Nathan A. Oyler, Bi-Botti C. Youan
Keywords
Related Articles
- EP ID EP681056
- DOI 10.1208/s12248-013-9546-7
- Views 50
- Downloads 0
Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine
The online version of this article (doi:10.1208/s12248-011-9308-3) contains supplementary material, which is available to authorized users.
Meeting Report: Metabolites in Safety Testing (MIST) Symposium—Safety Assessment of Human Metabolites: What’s REALLY Necessary to Ascertain Exposure Coverage in Safety Tests?
In the 2012 AAPS metabolites in safety testing (MIST) symposium held in Chicago, IL, USA, on October 15, 2012, regulatory experts and industrial scientists joined together to discuss their perspectives and strategies in...
Pharmacodynamic parameter estimation: Population size versus number of samples
The purpose of this study was to evaluate the effects of population size, number of samples per individual, and level of interindividual variability (IIV) on the accuracy and precision of pharmacodynamic (PD) parameter e...
Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling
Precision medicine promises to improve both the efficacy and safety of therapeutic products by better informing why some patients respond well to a drug, and some experience adverse reactions, while others do not. Pharma...
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration
Highly variable (HV) drugs are defined as those for which within-subject variability (%CV) in bioequivalence (BE) measures is 30% or greater. Because of this high variability, studies designed to show whether generic HV...